• House OKs bill bolstering medical research, drug approvals

    7 days ago - By News OK

    WASHINGTON - The House easily approved a sweeping biomedical bill Wednesday that would help drug and medical device companies win swifter government approval of their products, boost disease research and drug-abuse spending and revamp federal mental health programs.
    The compromise, which envisions spending $6.3 billion over the next decade, was condemned by consumer groups and some Democrats as a present to drugmakers that promised only paltry spending increases for underfunded federal programs.
    But their objections were overwhelmed by an alliance among Republicans, many Democrats and the...
    Read more ...

     

  • House Just Passed the Biggest Health Reform Bill Since Obamacare

    House Just Passed the Biggest Health Reform Bill Since Obamacare

    7 days ago - By Fortune

    The House of Representatives on Wednesday night overwhelmingly passed wide-ranging legislation meant to overhaul the drug approval process, boost biomedical research, and many other significant health-related policies. The so-called 21st Century Cures Act was approved on a 392-26 vote and will head to the Senate for consideration next week.
    The bill aims to speed up the approval for drugs and medical devices through a variety of tweaks to the Food and Drug Administration . But it also encompasses a host of other big initiatives, including more than $5 billion in funding for the National...
    Read more ...

     

  • House bill would aid medical research, speed drug approvals

    House bill would aid medical research, speed drug approvals

    7 days ago - By News OK

    WASHINGTON - A sweeping biomedical bill glided toward House passage Wednesday that would help drug and medical device companies win swifter government approval of their products, boost disease research and drug-abuse spending and revamp federal mental health programs.
    The compromise measure, which envisions spending $6.3 billion over the next decade, was condemned by consumer groups and some Democrats as a present to drugmakers that promised only paltry spending increases for underfunded federal programs.
    But their objections were overwhelmed by an alliance among Republicans, many...
    Read more ...